Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$23.94 USD

23.94
500,274

+0.09 (0.38%)

Updated Apr 22, 2024 11:55 AM ET

After-Market: $24.06 +0.12 (0.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alkermes (ALKS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises

by Zacks Equity Research

Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.

Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised

by Zacks Equity Research

Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.

BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study

by Zacks Equity Research

BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.

Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data

by Zacks Equity Research

Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.

Frequency (FREQ) Up 77% on Merger Deal With Korro Bio

by Zacks Equity Research

Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.

Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion

by Zacks Equity Research

Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.

Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio

by Zacks Equity Research

For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.

Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill

by Zacks Equity Research

Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.

First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback

by Zacks Equity Research

Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.

Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder

by Zacks Equity Research

If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.

Are Medical Stocks Lagging Alkermes (ALKS) This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Haemonetics (HAE) have performed compared to their sector so far this year.

Here's Why Investors Should Add Encompass Health (EHC) to Portfolio

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.

Implied Volatility Surging for Alkermes (ALKS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.

Here's Why Alkermes (ALKS) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Factors That Make Universal Health (UHS) an Attractive Bet Now

by Zacks Equity Research

Universal Health (UHS) remains well-poised for growth on the resumption of elective surgeries, a diversified treatment network and solid cash reserves.

Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer

by Zacks Equity Research

Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.

Here's Why You Should Add Alkermes (ALKS) to Your Portfolio

by Zacks Equity Research

Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Masimo (MASI) have performed compared to their sector so far this year.

Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View

by Zacks Equity Research

Alkermes (ALKS) receives final award in arbitration proceedings with partner Janssen. It also raises its financial outlook for 2023.

Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Vertex (VRTX) Down 6% Since Last Earnings Report?

by Zacks Equity Research

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.